1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians. 2018;68(1):7-30.
2. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65(2):87-108.
3. Amin RW, Ross AM, Lee J, et al. Patterns of ovarian cancer and uterine cancer mortality and incidence in the contiguous USA. The Science of the total environment. 2019;697:134128.
4. Yeung TL, Leung CS, Yip KP, et al. Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. American journal of physiology Cell physiology. 2015;309(7):C444-456.
5. Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015;5(5):402-418.
6. Petrie RJ, Doyle AD, Yamada KM. Random versus directionally persistent cell migration. Nature reviews Molecular cell biology. 2009;10(8):538-549.
7. Bisi S, Disanza A, Malinverno C, et al. Membrane and actin dynamics interplay at lamellipodia leading edge. Curr Opin Cell Biol. 2013;25(5):565-573.
8. Machesky LM. Lamellipodia and filopodia in metastasis and invasion. FEBS Lett. 2008;582(14):2102-2111.
9. Roche J. The Epithelial-to-Mesenchymal Transition in Cancer. Cancers. 2018;10(2).
10. Xue G, Hemmings BA. PKB/Akt-dependent regulation of cell motility. Journal of the National Cancer Institute. 2013;105(6):393-404.
11. Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nature reviews Cancer. 2009;9(6):415-428.
12. Ip CK, Cheung AN, Ngan HY, et al. p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene. 2011;30(21):2420-2432.
13. Yoshizaki H, Mochizuki N, Gotoh Y, et al. Akt-PDK1 complex mediates epidermal growth factor- induced membrane protrusion through Ral activation. Molecular biology of the cell. 2007;18(1):119-128.
14. Kwiatkowska A, Symons M. Signaling determinants of glioma cell invasion. Advances in experimental medicine and biology. 2013;986:121-141.
15. Takami Y, Higashi M, Kumagai S, et al. The activity of RhoA is correlated with lymph node metastasis in human colorectal cancer. Digestive diseases and sciences. 2008;53(2):467-473.
16. Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nature clinical practice Oncology. 2008;5(10):577-587.
17. Schwanhausser B, Busse D, Li N, et al. Corrigendum: Global quantification of mammalian gene expression control. Nature. 2013;495(7439):126-127.
18. Wurth L. Versatility of RNA-Binding Proteins in Cancer. Comparative and functional genomics. 2012;2012:178525.
19. Glisovic T, Bachorik JL, Yong J, et al. RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett. 2008;582(14):1977-1986.
20. Raineri I, Wegmueller D, Gross B, et al. Roles of AUF1 isoforms, HuR and BRF1 in ARE-dependent mRNA turnover studied by RNA interference. Nucleic acids research. 2004;32(4):1279-1288.
21. Rajkowitsch L, Chen D, Stampfl S, et al. RNA chaperones, RNA annealers and RNA helicases. RNA Biol. 2007;4(3):118-130.
22. Liao B, Hu Y, Brewer G. Competitive binding of AUF1 and TIAR to MYC mRNA controls its translation. Nat Struct Mol Biol. 2007;14(6):511-518.
23. Bayfield MA, Yang R, Maraia RJ. Conserved and divergent features of the structure and function of La and La-related proteins (LARPs). Biochim Biophys Acta. 2010;1799(5-6):365-378.
24. Kechavarzi B, Janga SC. Dissecting the expression landscape of RNA-binding proteins in human cancers. Genome biology. 2014;15(1):R14.
25. Guo Y, Tian P, Yang C, et al. Silencing the double-stranded RNA binding protein DGCR8 inhibits ovarian cancer cell proliferation, migration, and invasion. Pharmaceutical research. 2015;32(3):769-778.
26. Sommer G, Rossa C, Chi AC, et al. Implication of RNA-binding protein La in proliferation, migration and invasion of lymph node-metastasized hypopharyngeal SCC cells. PloS one. 2011;6(10):e25402.
27. Petz M, Them N, Huber H, et al. La enhances IRES-mediated translation of laminin B1 during malignant epithelial to mesenchymal transition. Nucleic acids research. 2012;40(1):290-302.
28. Hopkins TG, Mura M, Al-Ashtal HA, et al. The RNA-binding protein LARP1 is a post- transcriptional regulator of survival and tumorigenesis in ovarian cancer. Nucleic acids research. 2016;44(3):1227-1246.
29. Ye L, Lin ST, Mi YS, et al. Overexpression of LARP1 predicts poor prognosis of colorectal cancer and is expected to be a potential therapeutic target. Tumour Biol. 2016;37(11):14585-14594.
30. Cheng Y, Jin Z, Agarwal R, et al. LARP7 is a potential tumor suppressor gene in gastric cancer. Laboratory investigation; a journal of technical methods and pathology. 2012;92(7):1013-1019.
31. Bai SW, Herrera-Abreu MT, Rohn JL, et al. Identification and characterization of a set of conserved and new regulators of cytoskeletal organization, cell morphology and migration. BMC biology. 2011;9:54.
32. Seetharaman S, Flemyng E, Shen J, et al. The RNA-binding protein LARP4 regulates cancer cell migration and invasion. Cytoskeleton (Hoboken). 2016;73(11):680-690.
33. Reichlin M. Current perspectives on serological reactions in SLE patients. Clinical and experimental immunology. 1981;44(1):1-10.
34. Sommer G, Dittmann J, Kuehnert J, et al. The RNA-binding protein La contributes to cell proliferation and CCND1 expression. Oncogene. 2011;30(4):434-444.
35. Al-Ejeh F, Darby JM, Brown MP. The La autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(18 Pt 2):5509s-5518s.
36. Brenet F, Socci ND, Sonenberg N, et al. Akt phosphorylation of La regulates specific mRNA translation in glial progenitors. Oncogene. 2009;28(1):128-139.
37. Trotta R, Vignudelli T, Candini O, et al. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer cell. 2003;3(2):145-160.
38. Tang J, Huang ZM, Chen YY, et al. A novel inhibitor of human La protein with anti-HBV activity discovered by structure-based virtual screening and in vitro evaluation. PloS one. 2012;7(4):e36363.
39. Bousquet-Antonelli C, Deragon JM. A comprehensive analysis of the La-motif protein superfamily. Rna. 2009;15(5):750-764.
40. Xie C, Huang L, Xie S, et al. LARP1 predict the prognosis for early-stage and AFP-normal hepatocellular carcinoma. Journal of translational medicine. 2013;11:272.
41. Burrows C, Abd Latip N, Lam SJ, et al. The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration. Nucleic acids research. 2010;38(16):5542-5553.
42. Tcherkezian J, Cargnello M, Romeo Y, et al. Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5'TOP mRNA translation. Genes & development. 2014;28(4):357- 371.
43. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316(5828):1160-1166.
44. Hsu PP, Kang SA, Rameseder J, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011;332(6035):1317- 1322.
45. Yu Y, Yoon SO, Poulogiannis G, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011;332(6035):1322-1326.
46. Hsieh AC, Liu Y, Edlind MP, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012;485(7396):55-61.
47. Valavanis C, Wang Z, Sun D, et al. Acheron, a novel member of the Lupus Antigen family, is induced during the programmed cell death of skeletal muscles in the moth Manduca sexta. Gene. 2007;393(1-2):101-109.
48. Glenn HL, Wang Z, Schwartz LM. Acheron, a Lupus antigen family member, regulates integrin expression, adhesion, and motility in differentiating myoblasts. American journal of physiology Cell physiology. 2010;298(1):C46-55.
49. Wang Z, Glenn H, Brown C, et al. Regulation of muscle differentiation and survival by Acheron. Mechanisms of development. 2009;126(8-9):700-709.
50. Shao R, Scully SJ, Jr., Yan W, et al. The novel lupus antigen related protein acheron enhances the development of human breast cancer. International journal of cancer. 2012;130(3):544-554.
51. Ji X, Lu H, Zhou Q, et al. LARP7 suppresses P-TEFb activity to inhibit breast cancer progression and metastasis. eLife. 2014;3:e02907.
52. Biewenga P, Buist MR, Moerland PD, et al. Gene expression in early stage cervical cancer. Gynecologic oncology. 2008;108(3):520-526.
53. Merret R, Martino L, Bousquet-Antonelli C, et al. The association of a La module with the PABP- interacting motif PAM2 is a recurrent evolutionary process that led to the neofunctionalization of La- related proteins. Rna. 2013;19(1):36-50.
54. Schaffler K, Schulz K, Hirmer A, et al. A stimulatory role for the La-related protein 4B in translation. Rna. 2010;16(8):1488-1499.
55. Yang R, Gaidamakov SA, Xie J, et al. La-related protein 4 binds poly(A), interacts with the poly(A)- binding protein MLLE domain via a variant PAM2w motif, and can promote mRNA stability. Molecular and cellular biology. 2011;31(3):542-556.
56. Albrecht M, Lengauer T. Survey on the PABC recognition motif PAM2. Biochemical and biophysical research communications. 2004;316(1):129-138.
57. Amrani N, Ghosh S, Mangus DA, et al. Translation factors promote the formation of two states of the closed-loop mRNP. Nature. 2008;453(7199):1276-1280.
58. Goss DJ, Kleiman FE. Poly(A) binding proteins: are they all created equal? Wiley interdisciplinary reviews RNA. 2013;4(2):167-179.
59. Adams DR, Ron D, Kiely PA. RACK1, A multifaceted scaffolding protein: Structure and function. Cell communication and signaling : CCS. 2011;9:22.
60. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nature reviews Cancer. 2009;9(3):167-181.
61. Bai H, Li H, Li W, et al. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. Oncotarget. 2015;6(28):25520-25532.
62. Kitatani K, Usui T, Sriraman SK, et al. Ceramide limits phosphatidylinositol-3-kinase C2beta- controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid. Oncogene. 2016;35(21):2801-2812.
63. Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279-3290.
64. Heerboth S, Housman G, Leary M, et al. EMT and tumor metastasis. Clin Transl Med. 2015;4:6.
65. Lee YK, Park NH. Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers. Gynecologic oncology. 2009;112(3):475-480.
66. Ridley AJ. Rho GTPase signalling in cell migration. Curr Opin Cell Biol. 2015;36:103-112.
67. Schmitz AA, Govek EE, Bottner B, et al. Rho GTPases: signaling, migration, and invasion. Exp Cell Res. 2000;261(1):1-12.
68. Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19(2):197-208.
69. Zhu Y, Tian Y, Du J, et al. Dvl2-dependent activation of Daam1 and RhoA regulates Wnt5a- induced breast cancer cell migration. PloS one. 2012;7(5):e37823.
70. Pille JY, Denoyelle C, Varet J, et al. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther. 2005;11(2):267-274.
71. Hwang YS, Hodge JC, Sivapurapu N, et al. Lysophosphatidic acid stimulates PC-3 prostate cancer cell Matrigel invasion through activation of RhoA and NF-kappaB activity. Mol Carcinog. 2006;45(7):518- 529.
72. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.
73. Faried A, Faried LS, Usman N, et al. Clinical and prognostic significance of RhoA and RhoC gene expression in esophageal squamous cell carcinoma. Ann Surg Oncol. 2007;14(12):3593-3601.
74. Fritz G, Brachetti C, Bahlmann F, et al. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer. 2002;87(6):635-644.
75. Kamai T, Yamanishi T, Shirataki H, et al. Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004;10(14):4799-4805.
76. Somlyo AV, Bradshaw D, Ramos S, et al. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochemical and biophysical research communications. 2000;269(3):652-659.
77. Matsuoka T, Yashiro M. Rho/ROCK signaling in motility and metastasis of gastric cancer. World J Gastroenterol. 2014;20(38):13756-13766.
78. Chen S, Wang J, Gou WF, et al. The involvement of RhoA and Wnt-5a in the tumorigenesis and progression of ovarian epithelial carcinoma. Int J Mol Sci. 2013;14(12):24187-24199.
79. Horiuchi A, Imai T, Wang C, et al. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Laboratory investigation; a journal of technical methods and pathology. 2003;83(6):861-870.
80. Horiuchi A, Kikuchi N, Osada R, et al. Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer. Cancer Sci. 2008;99(12):2532-2539.
81. Wang X, Jiang W, Kang J, et al. Knockdown of RhoA expression alters ovarian cancer biological behavior in vitro and in nude mice. Oncol Rep. 2015;34(2):891-899.
82. Vega FM, Fruhwirth G, Ng T, et al. RhoA and RhoC have distinct roles in migration and invasion by acting through different targets. The Journal of cell biology. 2011;193(4):655-665.
論文の公開元へ
